Flow Neuroscience announced September 16 that its FL-100 headset is now available by prescription across the United States, nine months after the device cleared the FDA’s premarket approval process. The company is calling FL-100 the first FDA-approved at-home transcranial direct current stimulation, or tDCS, treatment for depression in the US market. On the narrow terms that claim is bounded to, an approved home-use tDCS device for depression, that appears to hold: Flow’s closest competitors in the category, Soterix Medical and Sooma Medical, are still running FDA-monitored pivotal trials under investigational device exemptions, not completed approvals. What launched this week is not new regulatory news. It is a commercial pathway, prescription plus telehealth evaluation, built on top of an approval FDA granted in December.

What the approval covers

FDA’s decision on PMA P230024 is dated December 8, 2025, roughly nine months before this launch announcement. The approved indication is narrower than “treatment for depression”: FL-100 is authorized for moderate to severe major depressive disorder in the current episode, as monotherapy or an adjunct to medication, in patients 18 and older who are not considered treatment-refractory. That population boundary matters for anyone reading the release as a blanket depression treatment. It is also a Class III device, the FDA’s highest-scrutiny category, following a 2019 federal order that specifically required any cranial electrotherapy device carrying a depression claim to go through full premarket approval rather than the lighter 510(k) clearance that covers the same device category’s anxiety and insomnia claims. Flow’s underlying efficacy data, a sham-controlled pivotal trial published in Nature Medicine, used the same at-home, app-guided protocol the company is now commercializing, which is a cleaner match between trial conditions and real-world use than most at-home device launches can claim.

What changed this week

The new element is the delivery model, not the science or the approval. Patients can be evaluated by a clinician in person or through Flow Care, the company’s own telehealth pathway staffed by independent licensed professionals, to determine whether a prescription is appropriate. Once prescribed, the FL-100 headset and companion app handle treatment delivery and adherence tracking, with data shared back to the prescribing clinician. That structure lowers the practical barrier between a patient and a Class III neuromodulation device: no in-clinic administration, no dedicated treatment site, no equipment beyond a headset and a phone. TMS and esketamine, the two device- and drug-based alternatives Flow is most directly positioned against, both require supervised, in-clinic administration under their own FDA-authorized conditions of use. FL-100’s approval does not.

What the release does not answer

Flow disclosed no price, no insurance or reimbursement pathway, and no CPT or payer coverage decision for FL-100 in the US. Reimbursement is the standard barrier for a new device category, not a Flow-specific gap, but it is the fact that determines whether “available by prescription” translates into patients who can afford to fill that prescription. The company’s usage figures, more than 65,000 people globally and more than 1,200 prescribing clinicians, are Flow’s own reported numbers, not independently verified, and they describe international use built mostly under the device’s earlier UK and European authorizations, not US experience: FL-100 has been sold in the US only since September 1. Whether the telehealth-plus-home-device model that built that international base performs the same way once US payers, and US patients’ out-of-pocket costs, enter the picture is not something this release, or any data available yet, can settle.

The tradeoff

The commercial case for FL-100 is structural: a Class III device that patients can use without a treatment site, prescribed through a telehealth pathway that doesn’t require finding a clinician who already offers neuromodulation. That cuts against the access friction described above. What FL-100 trades away is the supervision TMS and esketamine build into their clinic visits. Flow’s substitute, app-based adherence tracking and remote clinician monitoring instead of in-person administration, is the same structure its pivotal trial tested, which is a stronger basis than most home-use launches have. It has not yet been tested at US commercial scale, under US payer and pricing conditions, outside a trial’s recruitment and monitoring infrastructure.

What to watch

Three things would move this from a launch announcement to a market fact: a payer or CMS coverage decision for FL-100, since none is disclosed here; a first US real-world adherence or outcomes readout, since the trial data behind the approval was not collected under US commercial conditions; and whether Soterix or Sooma’s own investigational programs reach a PMA decision, which would end Flow’s first-mover window in approved at-home tDCS for depression.